ASH 2022 | The use of tafasitamab and lenalidomide in R/R DLBCL
Umberto Vitolo
• 12 Dec 2022
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on the mechanism of action and efficacy of tafasitamab alone or in combination with other agents such as rituximab and lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting data from the L-MIND study (NCT02399085). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Seagen, Genmab, Incyte, Costellation, Bayer, Regeneron: Consultancy; AbbVie, Incyte, Janssen, Gilead Sciences: Speakers Bureau.
